Novel Bioengineering Approach to Fully Restore Thyroid Function in Panhypopituitarism
Authors/Creators
Description
Panhypopituitarism is a rare endocrine disorder causing multi-hormonal deficiencies, including central hypothyroidism due to the loss of thyroid-stimulating hormone (TSH). Current hormone replacement therapies fail to replicate normal thyroid function, leading to persistent metabolic imbalances. This paper proposes a bioengineered TSH-secreting implant that autonomously monitors thyroid hormone levels and adjusts TSH secretion in real time, effectively restoring physiological feedback control. This novel synthetic pituitary-thyroid axis combines genetic circuits, encapsulated bioengineered cells, and microfluidic sensing to dynamically regulate thyroid hormone levels, eliminating the need for daily levothyroxine administration. If successful, this approach could revolutionize endocrine therapy by moving from hormone replacement to true endocrine restoration.
Files
Novel Bioengineering Approach to Fully Restore Thyroid Function in Panhypopituitarism.pdf
Additional details
Dates
- Available
-
2025-02-06
References
- • Suga et al. (2021) – notes that conventional hormone replacement cannot replicate physiological hormone dynamics, leaving patients at risk of severe deficiencies
- • McAninch & Bianco (2016) – observes that standard T4 therapy often fails to restore normal thyroid hormone action in all tissues, as many patients have persistent hypothyroid symptoms
- • Drug Target Review (2016) – highlights that stem-cell derived pituitary cells can integrate feedback control and potentially cure hypopituitarism rather than merely treat it
- • Kano et al. (2023) – demonstrates that combined hypothalamus-pituitary organoids from stem cells secrete hormones with intact positive/negative feedback, and can engraft in vivo to restore endocrine function in hypopituitarism models
- • Saxena et al. (2016) – designed a synthetic gene circuit in implanted cells that senses thyroid hormone levels and produces a therapeutic protein in response, effectively restoring thyroid feedback control in an animal model of hyperthyroidism
- • Zhang et al. (2015) – review of TSH receptor ligands; reports the development of a potent small-molecule TSHR agonist that can stimulate thyroid activity in vitro and in mice
- • Ishii et al. (1968) – classic experiment showing vagus nerve stimulation increases thyroid hormone release acutely, but to a lesser extent than TSH stimulation
- • Chen et al. (2022) – discusses cell-based therapies and notes that engineered cells are typically encapsulated in semipermeable membranes to protect from immune rejection while allowing molecular exchange